SCHEMBL2867437

SCHEMBL2867437

O=C(NCc1cc2c(-c3cccc(F)c3)n[nH]c2cc1F)c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.47
MAP2K4 P45985 3/20 0.46
DGAT2 Q96PD7 2/20 0.46
NPC1 O15118 1/20 0.46
KMT2A Q03164 1/20 0.45
PTAFR P25105 1/20 0.45
MAPK1 P28482 5/20 0.45
MAP2K7 O14733 1/20 0.44
WNT1 P04628 1/20 0.44
DYRK1A Q13627 1/20 0.44
MAPK3 P27361 2/20 0.44
PIM1 P11309 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2863237 0.91 CSNK1D (0.52) CSNK1DMAP2K4DGAT2MAPK1MAPK3
SCHEMBL2870798 0.88 NTRK1 (0.52) CSNK1DDGAT2KMT2AMAPK1
SCHEMBL13635746 0.86 CSNK1D (0.49) CSNK1DMAP2K4DGAT2MAPK1MAPK3
SCHEMBL13198273 0.86 DGAT2 (0.50) CSNK1DDGAT2MAPK1WNT1DYRK1A
SCHEMBL2862635 0.84 DGAT2 (0.56) CSNK1DDGAT2NPC1
SCHEMBL2870355 0.84 MAPK1 (0.50) CSNK1DMAP2K4MAPK1MAPK3
SCHEMBL4332113 0.83 KDM4E (0.52) MAP2K4KMT2APTAFRMAPK1MAP2K7
SCHEMBL2863001 0.79 NTRK1 (0.56) CSNK1DMAP2K4DGAT2MAPK1MAPK3
SCHEMBL4333984 0.78 PTAFR (0.51) KMT2APTAFRMAPK1MAPK3
SCHEMBL4341451 0.78 KDM4E (0.49) MAP2K4KMT2APTAFRMAPK1MAP2K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
EP-1380576-B1 1H-INDAZOLE COMPOUNDS INHIBITING JNK EISAI R&D MAN CO LTD (JP) 2009-11-25 EP disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
CN-1300116-C 1H-indazole compounds EISAI CO LTD (JP) 2007-02-14 CN disclosed
US-6982274-B2 1H-indazole compound EISAI CO., LTD. (JP) 2006-01-03 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed
CN-1512987-A Novel 1H-indazole compound ������������ʽ���� 2004-07-14 CN disclosed
US-20040127538-A1 Novel 1h-indazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CSNK1D 134/4885MAP2K4 61/4885DGAT2 3122/4885
US-20040127538-A1 Novel 1h-indazole compound MAPK1, MAPK14, MAPK3 CSNK1D 90/4885MAP2K4 53/4885DGAT2 3665/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 CSNK1D 134/4885MAP2K4 61/4885DGAT2 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.